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ABSTRACT. 
Objective. This analysis aimed to evaluate the economic burden of patients with 
psoriatic arthritis (PsA) on the UK healthcare system and estimate the relationship 
between functional status and direct healthcare costs. 
Methods. Functional status (measured using the Health Assessment Questionnaire–
Disability Index [HAQ-DI]), demographics, disease history and healthcare resource 
use data were extracted from a cohort of patients at the Royal National Hospital for 
Rheumatic Diseases, Bath, UK. Each resource use item per patient was then 
allocated a unit cost. Linear regression models were used to predict costs as a 
function of HAQ-DI. Medication costs were not included in the primary analysis, 
which was carried out from the UK National Health Service perspective. 
Results. Data were available for 101 patients. Mean HAQ-DI score was 0.84 (SD 
0.75) and mean age at HAQ-DI measurement was 57.8 (SD 10.7). Total annual 
healthcare costs per patient, excluding medication costs, ranged between £174 and 
£8,854, with a mean of £1,586 (SD £1,639). A 1-point increase in HAQ-DI score was 
associated with an increase in total costs of £547.49 (SE £224), with secondary care 
consultations appearing to be the primary factor. Subgroup analyses suggested 
higher cost increases in patients with HAQ-DI scores 2–3 and with a disease 
duration >10 years. 
Conclusion. Patients with PsA have a significant economic burden on the 
healthcare system. Functional status is highly correlated with costs and appears to 
be driven mainly by the cost of secondary care consultations. Results were similar to 
previous studies in rheumatoid arthritis populations. 
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Psoriatic arthritis (PsA) is a chronic, systemic inflammatory joint disease that is often 
associated with the inflammatory skin condition, psoriasis. PsA affects the peripheral 
joints, axial skeleton, periarticular structures, skin and nails, with patients 
experiencing pain, swelling and joint tenderness. Joint damage is progressive, 
leading to reduced mobility and function, as well as impaired quality of life (1). Joint 
damage in PsA is significantly less marked than in rheumatoid arthritis (RA) after 
equivalent disease duration (2,3), and PsA was originally thought to be a milder 
condition than RA. However, the impact on patients’ quality of life is similar in the 2 
conditions (2,3), and PsA is now widely recognised to be as severe as RA (2).  
Current treatment options for PsA include non-steroidal anti-inflammatory 
drugs, disease-modifying antirheumatic drugs (such as methotrexate and 
sulfasalazine), biologic therapies (e.g. tumour necrosis factor, IL-17 and IL-12/23 
inhibitors), and apremilast (4-6). However, development of policies, 
recommendations and guidelines for management of patients requires an evaluation 
of both the different treatments available and the impact of these on the use of 
healthcare resources. Those involved in making clinical decisions need information 
about costs as well as evidence of efficacy. 
In RA, the relationship between cost and functional status is well documented 
(7,8). However, similar work in PsA is limited. In a recent economic evaluation, the 
relationship between functional status and costs was derived from an RA dataset 
rather than from patients with PsA (9). A further evaluation of biologics was 
inconclusive on the relationship between cost and functional status due to several 
uncertainties surrounding model parameters, including limited evidence for rebound 
following withdrawal of biologic therapy. Poole et al (10) demonstrated a relationship 
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between functional status and costs in PsA; however, their approach was limited by 
the use of separate patient cohorts for derivation of functional status and cost data. 
Here, we present the findings of an analysis designed to estimate the 
relationship between functional status and healthcare costs in PsA using data from 
patients in a single, longitudinal cohort. 
 
MATERIALS AND METHODS 
Data sources. Since 1989, patients with PsA at the Royal National Hospital for 
Rheumatic Diseases (RNHRD; Bath, UK) have been recruited into an observational 
cohort as part of their routine care. Patients who fulfil the CASPAR criteria for PsA 
(11,12) and attend the clinic every 3 to 6 months, depending on their clinical need, 
were included in this analysis. At each appointment, patients undergo a full clinical 
assessment, including 66 swollen and 68 tender joint counts, body surface area skin 
assessment, dactylitis and enthesitis count, and nail assessment. Patient-reported 
outcomes are also collected, including the Health Assessment Questionnaire‒
Disability Index (HAQ-DI). For the purposes of this study, a convenience sample of 
101 patients was selected from a total eligible cohort of 660 patients. 
Data from the HAQ-DI, which was originally developed for the assessment of 
physical function in RA (12), support its use in PsA (13,14). The index assesses 8 
categories of function; within each category, patients report how much difficulty they 
have in performing specific activities. The highest score within each category is 
taken as the overall score for that category; these are then added together and 
divided by the number of categories answered to give a summary score. Scores of 0 
to 1 gGenerally, represent mild to moderate functional difficulty is represented by 
scores of 0 to 1, scores of 1 to 2 represent moderate to severe functional difficulty is 
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represented by and scores of 1 to 2 to 3 indicate, and severe to very severe 
functional difficulty is represented by scores of 2 to 3 (15). 
Patients who had 6 months of health outcomes and resource use data before 
and after a HAQ-DI measurement were selected the RNHRD PsA cohort. Resource 
use data included tests and investigations, primary and secondary consultations, 
accident and emergency department (A&E) attendances, and hospital admissions 
(admitted care). Demographic, health outcomes and resource use data for eligible 
patients were extracted and entered into a database. In addition, a detailed 
questionnaire was sent to all eligible patients requesting permission to contact their 
general practitioner (GP) to obtain access to their prescription records. The 
questionnaire was used to corroborate electronic records relating to secondary care 
activities for each patient. Data covering the period 2011 to 2014 were extracted in 
January 2015. 
Following full data extraction, unit costs were allocated to all healthcare 
resource utilisation items for each patient in the study. Costs for hospital episodes 
were sourced from the published National Health Service reference costs datasets 
for 2012/2013 and 2014/2015 (16)(15). Where the reason for hospital admission was 
unclear, costs for elective procedures were assigned. With regards to outpatient 
activity, it was unclear for most appointment entries whether they were a first 
attendance, follow-up attendance, consultant-led attendance, or attendance by other 
clinical team members. In the absence of more detailed information, we assumed a 
follow-up appointment cost for all outpatient activity. Primary care costs were 
assigned according to whether the appointment was in person with a GP or nurse, or 
whether patients received a telephone call from their GP or nurse (17)(16). Costs for 
prescription medications were taken from the British National Formulary (18)(17) and 
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the NHS drug tariff (19)(18) where relevant. Detailed prescription information (e.g. 
dose, pack size) was missing for a large proportion of the medication data. These 
data were missing completely at random and therefore mean imputation methods 
were used to derive a complete dataset. 
The study was approved by the South West-Central Bristol NRES Committee 
(institutional review board approval number BA74/00-01) and was conducted in 
accordance with the Declaration of Helsinki. All patients signed informed consent. 
Statistical analyses. Statistical analyses were carried out using R software (R 
Foundation for Statistical Computing, Vienna, Austria) (20)(19). Linear regression 
modelling was used to predict cost data as a function of HAQ-DI and other predictors 
(age at the HAQ-DI measurement and gender). In addition to simple linear 
regression models, alternatives were considered with logarithmic transformation of 
cost outcomes, and quadratic transformation of the HAQ-DI predictor and 
generalised linear models with a gamma error distribution (using identity and inverse 
link functions). During model selection, Tt-tests were used to assess the significance 
of individual predictors with a null hypothesis that the predictor’s coefficient was zero. 
Models were simplified by removal of non-significant predictors. Model fit and 
predictive accuracy were compared by estimation of root mean squared error 
(RMSE), Akaike’s information criterion (a parameter-penalised measure of model fit) 
and examination of the distribution of residuals. As cost data were not normally 
distributed, standard errors (SEs), 95% confidence intervals and P values were 
estimated by bootstrap resampling (100,000 samples). 
Models including total healthcare costs (with medication costs) were non-
significant. Subsequently, models were explored for a subset of healthcare costs, 
excluding medication costs. Final model selection was therefore based on the 
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outcome ‘total cost without medication’ and the selected model was used to estimate 
the association between the HAQ-DI score and individual cost components (i.e. 
primary and secondary care consultations, tests and investigations, admitted care 
and A&E attendances). 
The following subgroups were analysed to determine if identified associations 
between the HAQ-DI score and cost remained approximately consistent: HAQ-DI 
cut-off (0 to <1, 1 to <2, ≥2), disease duration (<5 years, 5 to <10 years, ≥10 years) 
and gender. 
The analysis was carried out from the UK healthcare perspective. 
 
RESULTS 
The HAQ-DI, age at onset, age at HAQ-DI assessment, gender and cost data were 
collated for the study sample of 101 patients. Fifty-eight patients were female. Table 
1 shows patients’ characteristics, including the mean HAQ-DI score, age and 
disease duration. Total mean annual healthcare costs were £3,870 (SE £394) per 
patient. Medication costs were the largest component (£2,284 [SE £350]). For the 
subset of costs (excluding medication costs), the mean cost per patient was £1,586 
(SE £161) (Table 2). 
Models with total healthcare costs, including medication costs, were non-
significant. For analyses using the subset of costs without medications, age at HAQ-
DI assessment, disease duration and gender were not significant predictors of cost, 
so they were removed from the models. 
Table 3 shows the details of the simple regression model. The simple linear 
regression modelling residuals were moderately skewed to the right. Logarithmic 
transformation of cost normalised the distribution of residuals but increased RMSE; 
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the quadratic transformation of the HAQ-DI gave a similar RMSE to the linear model, 
but increased the Akaike’s information criterion. The generalised linear models with 
gamma distributed errors had a marginally higher RMSE than the linear model. The 
simple linear model was therefore selected as its coefficient (cost increase per unit 
increase in the HAQ-DI) allowed a simple interpretation with no significant loss in 
model fit compared with more complex strategies, and bootstrap resampling allowed 
robust estimation of confidence intervals as the model residuals were not normally 
distributed. 
The modelling showed that, in general, patients with a worse functional 
disease status (i.e. higher HAQ-DI scores) had higher total healthcare costs 
(excluding medication costs; Figure 1). However, some patients with low HAQ-DI 
scores had high healthcare costs and vice versa. Similar overall findings were 
observed when this analysis was repeated excluding the 6 patients whose total costs 
exceeded £5,000 (Supplementary Table 1). The estimated association of total 
costs without medication with the HAQ-DI score changed from £547/unit to 
£386/unit, as the excluded patients had high admitted care costs which correlated 
with the HAQ-DI score. A 1-point increase in the HAQ-DI score was associated with 
an estimated increase in total healthcare costs of £547.49 (Table 4). Costs 
associated with secondary care appeared to be the primary factor in the relationship 
between the HAQ-DI score and healthcare costs (Figure 2). Results from the model 
on log-transformed costs are provided in Supplementary Table 2. 
Results of the subgroup analyses (excluding medication costs) are shown in 
Table 4. There appeared to be a trend for greater cost increases per 1-point 
increase in the HAQ-DI score among males, patients with HAQ-DI scores ≥2, and 
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those who have had PsA for >10 years. Interestingly, patients with a HAQ-DI score 
of 0 to <1 had a greater cost increase than those with scores between 1 and 2.  
 
DISCUSSION 
This study demonstrates a relationship between disease severity in PsA and 
healthcare costs, with the estimated HAQ-DI score being a significant predictor of 
total healthcare costs. Total annual healthcare costs in PsA represent a significant 
burden for healthcare systems and increase markedly with increasing disease 
severity. When the cost of medications is excluded, secondary care consultations 
appear to be the main driver of the association between disease severity and cost. 
A previous study by Poole et al (10) also demonstrated an increase in costs 
with increasing HAQ-DI score in PsA. However, mean annual healthcare costs 
estimated in our study (£1,586, excluding medication costs) were higher than those 
estimated by Poole et al (10) (£1,446, including medication costs), suggesting that 
the economic burden of PsA may be greater than previously thought. One possible 
reason for this is that patients in our study were older (mean age, 57.8 vs. 46.7 years 
in the study by Poole et al (10)), which could mean more comorbidities, and had PsA 
for longer (almost 20 vs. 11 years in the study by Poole et al (10)). It is important to 
note that the study by Poole et al (10) was limited by the use of separate cohorts for 
the derivation of the HAQ-DI and resource use data; use of a single patient cohort in 
our study allowed more accurate mapping of the relationship between the HAQ-DI 
score and cost. 
Overall, our findings were similar to previous research in RA populations, 
showing a similar increase in costs with increasing disability, as measured by the 
HAQ-DI (9). In an analysis of 1,487 French patients with RA (mean disease duration, 
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18 years), the HAQ-DI score was a very strong predictor of costs and was 
significantly correlated with direct medical costs (8). Similarly, an analysis of 201 
Spanish patients with RA (mean disease duration, 7.7 years) showed a significant 
increase in costs with increasing HAQ-DI score (7). 
When the burden of articular disease and spinal/enthesitis/dactylitis/skin 
disease and extra-articular manifestations are considered, the total burden of 
disease in PsA is felt to be similar to RA. This is supported by studies demonstrating 
similar levels of HAQ (2,21,22)(2,20,21).  
In our sensitivity analyses using linear regression modelling to predict total 
cost as a function of disease duration, duration of 0 to <5 years or 5 to <10 years 
was not statistically significantly associated with total cost; however, the association 
between total cost and disease duration of >10 years was statistically significant. The 
point estimates for the 3 categories suggest a possible monotonic increase in total 
cost with increasing disease duration, but the number of patients in the lowest 2 
categories was small and the parameter estimates unstable. 
Our final model excluded medication costs, for which there was a substantial 
amount of missing information in the original dataset. Our use of mean imputation of 
medication costs may under-represent uncertainty in the relevant estimates; 
however, as we found no significant association between medication costs and 
HAQ-DI, more complex strategies such as multiple imputation would not change this 
conclusion. The exclusion of medication costs in our statistical model is a limitation of 
the study, as medication costs are likely to make a substantial contribution to the 
overall costs associated with PsA. In addition, PsA has an important impact on 
societal costs (23-26)(22-25). For example, a survey of 50 patients in Poland found 
those who were employed were absent from work for an average of 2.88 days/month 
Commented [A1]: Added this from bold text in 
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and had an on-the-job productivity loss of 24.1% (26)(25). A systematic review by 
Tillett et al (27)(26) showed that levels of work disability comprising absenteeism (i.e. 
absence from work) and presenteeism (i.e. reduced effectiveness at work) range 
from 16% to 39% in patients with PsA. A study of UK patients with PsA found 
absenteeism, presenteeism and productivity loss rates of 14%, 39% and 46%, 
respectively (28)(27). The findings from our study are therefore likely to 
underestimate the true burden of costs associated with PsA. 
Given the relatively small sample size, potential selection bias is another 
limitation of our study. The small number of patients sampled may not adequately 
reflect the diversity of PsA disease manifestations or severity. In addition, only those 
patients whose GP responded to a request for access to prescription data were 
included. This could have been avoided by making the decision not to include 
prescription data at an earlier stage. 
In conclusion, our study demonstrates that PsA can cause a significant 
burden on the resources of healthcare systems such as the National Health Service. 
Finally, it has also been demonstrated that there exists a significant relationship 
between functional status and healthcare costs in patients with PsA, although further 
research is needed to gain a deeper understanding of this relationship and aid 
decision makers in the development of policies and treatment guidelines. 
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Table 1. Patient characteristics. 
Characteristics Study Population 
Patients, N 101 
Age, mean (SD), years 57.83 (10.66) 
Sex, female / male, n (%) 58 (57) / 43 (43) 
HAQ-DI score, mean (SD) 0.84 (0.75) 
Disease duration, mean (SD), years 18.23 (11.26) 
HAQ-DI: Health Assessment Questionnaire‒Disability Index; SD: standard deviation. 
  
19 
Table 2. Healthcare costs per patient* by resource use category (₤/unit, 2016 
prices). 
Resource use category Mean (SD) Median (IQR) Range 
Tests £146 (£117) £126 (£137) £0 to £690 
A&E visit £14 (£35) £0 (£0) £0 to £154 
Primary care consultation £247 (£198) £195 (£256) £0 to £1,101 
Secondary care consultation £678 (£445) £594 (£445) £0 to £2,635 
Admitted care £502 (£1,415) £0 (£0) £0 to £6,660 
Medication costs £2,284 (£3,493) £390 (£3,560) £0 to £16,326 
Total costs £3,870 (£3,986) £2123 (£4,952) £175 to £17,771 
Total costs (excluding 
medication costs) 
£1,586 (£1,639) £1,111 (£1,213) £174 to £8,854 
* Based on study population of 101 patients, the n values used to calculate values 
shown may vary slightly across cost categories due to missing data. A&E: accident 
and emergency department; SD: standard deviation.  
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Table 3. Output results of the linear regression modelling. 
Covariate β (SE) P value 95% CI for β 
HAQ-DI total cost (excluding 
medications) 
£547 (£224) 0.006 197 to 1,120 
Intercept total cost (excluding 
medications) 
£1,128 (£200) <0.001 792 to 1,596 
Number of observations 101   
Log likelihood −887.1   
Akaike’s information criterion 1,780   
Adjusted R2 0.053   
CI: confidence interval; HAQ-DI: Health Assessment Questionnaire‒Disability Index;  
SE: standard error.  
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Table 4. Results of the regression modelling: estimated HAQ-DI coefficient. 
 Estimated HAQ-DI coefficient from  
regression of costs in HAQ-DI (£/unit) 
 Estimate (SE)* 95% CI P value 
Primary analysis    
Tests £21.45 (£14) −7 to 48 0.121 
A&E visit £15.67 (£6) 7 to 29 0.001 
Primary care consultation £69.98 (£25) 21 to 117 0.007 
Secondary care consultation £278.14 (£50) 185 to 381 <0.001 
Medications £58.07 (£447) −788 to 966 0.903 
Admitted care £162.25 (£200) −131 to 716 0.437 
Total costs (w/o meds) £547.49 (£224) 197 to 1,120 0.006 
Sensitivity analyses for total costs (excluding medication cost) 
Disease duration    
 0 to <5 years (n=6) £−76.97 (£499) −1,335 to 779 0.852 
 5 to <10 years (n=12) £390.47 (£834) −275 to 4,118 0.656 
 ≥10 years (n=63) £626.50 (£264) 212 to 1,298 0.008 
HAQ-DI    
 0 to <1 (n=58) £981.68 (£572) −15 to 2,263 0.066 
 1 to <2 (n=33) £116.88 (£904) −2,066 to 1,615 0.849 
 ≥2 (n=10) £3,340.13 (£3,693) 883 to 15,303 0.051 
Gender    
 Female (n=58) £480.3 (£377) −123 to 1,407 0.208 
 Male (n=43) £520.92 (£264) 148 to 1,273 0.014 
* Bootstrapped SE. A&E: accident and emergency department; CI: confidence 
interval; HAQ-DI: Health Assessment Questionnaire‒Disability Index; SE: standard 
error.  
22 
Figure 1. Relationship between HAQ-DI and total healthcare costs: a regression 




Figure 2. HAQ-DI coefficient for resource use categories. Coefficient for medications 
(£58.07) and confidence interval (−788 to 966) not shown. A&E: accident and 




Supplementary Table 1. Results of the regression model excluding 6 patients 
whose total costs without medications exceeded £5,000: estimated HAQ-DI 
coefficient. 
 Estimated HAQ-DI coefficient from  
regression of costs in HAQ-DI (£/unit) 
Primary analysis Estimate (SE)* 95% CI P value 
Tests £18.19 (£15) −12 to 46 0.209 
A&E visit £17.27 (£6) 7 to 31 0.001 
Primary care consultation £67.26 (£27) 14 to 119 0.015 
Secondary care consultation £264.55 (£51) 170 to 369 <0.001 
Medications £−57.78 (£439) −873 to 857 0.884 
Admitted care £18.86 (£48.389) −101 to 97 0.654 
Total costs (without 
medication) 
£386.13 (£93) 202 to 566 <0.001 
A&E: accident and emergency department; CI: confidence interval; HAQ-DI: Health 
Assessment Questionnaire–Disability Index; SE: standard error. 
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Supplementary Table 2. Results of the regression modelling: estimated HAQ-DI 
coefficient from regression of log10 (costs +1). 
 Estimated HAQ-DI coefficient from  
regression of log10 (costs + 1) in HAQ-DI (£/unit) 
 
Estimate (SE)* Estimate ^10 (CI) P value 
Tests 0.129 (0.066) 1.344 (0.966 to 1.814) 0.053 
A&E visit 0.300 (0.089) 1.997 (1.331 to 2.995) 0.001 
Primary care consultation 0.130 (0.070) 1.350 (0.981 to 1.856) 0.065 
Secondary care consultation 0.147 (0.050) 1.403 (1.116 to 1.764) 0.004 
Medications 0.073 (0.128) 1.182 (0.660 to 2.118) 0.571 
Admitted care 0.275 (0.173) 1.882 (0.854 to 4.149) 0.116 
Total costs (without 
medication) 
0.172 (0.042) 1.485 (1.223 to 1.803) <0.001 
 
 
